Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 4, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) today announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which takes place January 11-14, 2021. Neovasc President and Chief Executive Officer Fred Colen, Chief Operating Officer Bill Little, and Chief Financial Officer Chris Clark will be available for one-on-one investor meetings during the event; meetings may be requested through H.C. Wainwright. Additionally, a webcast of Neovasc's recorded company presentation will be available on demand via the H.C. Wainwright conference site beginning at 6:00 am ET on January 11, and on the Neovasc website at https://www.neovasc.com/presos/.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.

Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
[email protected]

Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71317

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).